Literature DB >> 2117566

Identification and characterization of transcripts from the neurofibromatosis 1 region: the sequence and genomic structure of EVI2 and mapping of other transcripts.

R M Cawthon1, P O'Connell, A M Buchberg, D Viskochil, R B Weiss, M Culver, J Stevens, N A Jenkins, N G Copeland, R White.   

Abstract

Mapping of the EVI2 gene between the translocation breakpoints of two patients with neurofibromatosis type 1 (NF1), combined with the likely role of its murine homolog in neoplastic disease, implicates EVI2 as a possible candidate for the NF1 gene. We report here the expression of a 1.6-kb EVI2 transcript in normal human brain and peripheral blood mononuclear cells. Sequencing studies predict an EVI2 protein of 232 amino acids that contains an N-terminal signal peptide, an extracellular domain with five potential glycosylation sites, a single hydrophobic transmembrane domain with a leucine zipper, and a hydrophilic cytoplasmic domain. These features are all well-conserved with respect to the mouse Evi-2 protein and are consistent with the hypothesis that EVI2 is a membrane protein that may complex with itself and/or other proteins within the membrane, perhaps to function as part of a cell-surface receptor. In the course of these studies we have also identified three other transcripts (classes of cDNAs) from the NF1 region. Two of these transcripts map between the NF1 translocation breakpoints; the remaining transcript maps just outside this region.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117566     DOI: 10.1016/0888-7543(90)90199-5

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  35 in total

1.  Gene assignment in Ateles paniscus chamek (Platyrrhini, Primates). Allocation of 18 markers of human syntenic groups 1, 2, 7, 14, 15, 17 and 22.

Authors:  H N Seuánez; C R Lima; B Lemos; C R Bonvicino; M A Moreira; F C Canavez
Journal:  Chromosome Res       Date:  2001       Impact factor: 5.239

Review 2.  Molecular biology of neurological diseases.

Authors:  W J Cumming
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

3.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-04-25       Impact factor: 16.971

4.  Perioperative management of neurofibromatosis type 1.

Authors:  Charles J Fox; Samir Tomajian; Aaron J Kaye; Stephanie Russo; Jacqueline Volpi Abadie; Alan D Kaye
Journal:  Ochsner J       Date:  2012

5.  A BamHI polymorphism in the human EVI2A gene (human homolog of the murine gene Evi-2).

Authors:  W Xu; L Liu; B A Ponder
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

Review 6.  The silence RNA keeps: cis mechanisms of RNA mediated epigenetic silencing in mammals.

Authors:  Cristina Tufarelli
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-01-29       Impact factor: 6.237

7.  Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA.

Authors:  Kian-Huat Lim; Donita C Brady; David F Kashatus; Brooke B Ancrile; Channing J Der; Adrienne D Cox; Christopher M Counter
Journal:  Mol Cell Biol       Date:  2009-11-09       Impact factor: 4.272

Review 8.  Mouse models of glioblastoma: lessons learned and questions to be answered.

Authors:  Loury Janbazian; Jason Karamchandani; Sunit Das
Journal:  J Neurooncol       Date:  2014-02-13       Impact factor: 4.130

9.  Expansion of the RASopathies.

Authors:  William E Tidyman; Katherine A Rauen
Journal:  Curr Genet Med Rep       Date:  2016-07-01

10.  Linkage disequilibrium in the neurofibromatosis 1 (NF1) region: implications for gene mapping.

Authors:  L B Jorde; W S Watkins; D Viskochil; P O'Connell; K Ward
Journal:  Am J Hum Genet       Date:  1993-11       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.